Malignant Ascites - Pipeline Insight, 2022

Malignant Ascites - Pipeline Insight, 2022

DelveInsight’s, “Malignant Ascites - Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Malignant Ascites Understanding

Malignant Ascites: Overview

Malignant ascites accounts for approximately 7-10% of all cases of ascites. A number of mechanisms exist whereby cancer can cause ascites, and its development is not always synonymous with a diagnosis of peritoneal carcinomatosis. The two main causes observed in the Beatson West of Scotland Cancer Centre are: 1) Peritoneal carcinomatosis secondary to malignancies of ovarian and urological origin. In these cases, accumulation of ascites results from blockage of the draining lymphatic channels and increased vascular permeability and 2) Colonic, gastric, breast, pancreatic, and lung cancers with extensive liver metastases which may result in functional cirrhosis and portal hypertension. Ascites in women with a new diagnosis of epithelial ovarian cancer is not necessarily associated with a severely limited prognosis; such patients may live for years once appropriate anti-cancer treatment is established. When a patient develops ascites in the setting of a non-ovarian cancer, the prognosis is usually poor and often less than three months. In women with a new diagnosis of epithelial ovarian cancer, the initial treatment of choice is surgical debulking with chemotherapy. In the presence of large volume ascites, or if surgical debulking is not feasible then primary chemotherapy can be given with delayed primary surgery after 3 cycles of chemotherapy. In patients with malignant ascites secondary to other solid tumours, prognosis is generally poor and the role of surgery is not established. Palliative systemic therapy is sometimes appropriate, with the treatment regimen tailored towards the primary site of cancer.

""Malignant Ascites - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant Ascites pipeline landscape is provided which includes the disease overview and Malignant Ascites treatment guidelines. The assessment part of the report embraces, in depth Malignant Ascites commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant Ascites collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Malignant Ascites.

In the coming years, the Malignant Ascites market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Malignant Ascites R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

A detailed portfolio of major pharma players who are involved in fueling the Malignant Ascites treatment market. Several potential therapies for Malignant Ascites are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Malignant Ascites market size in the coming years.

Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Malignant Ascites) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Malignant Ascites Emerging Drugs Chapters

This segment of the Malignant Ascites report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant Ascites Emerging Drugs

SCB-313: Sichuan Clover Biopharmaceuticals, Inc.

Utilizing the Trimer-Tag™ technology platform, the company has successfully designed and developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. The drug is currently in Phase I stage of clinical trial evaluation to treat Malignant Ascites.

M 701: YZY Biopharma

Leveraging on YZY Biopharm in house proprietary Y-BODY platform, M701 bispecific antibody is designed to bind tumor cells through anti-EpCAM and immune cells through CD3 and FcgR. Close contact of immune cells and tumor cells induced by M701 can cause effective tumor cell lysis and T cell stimulation. With Fc builtin, M701 is stable and has long half-life. Manufacturing process was developed quickly through established development platform.

Further product details are provided in the report……..

Malignant Ascites: Therapeutic Assessment

This segment of the report provides insights about the different Malignant Ascites drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Malignant Ascites

There are approx. 3+ key companies which are developing the therapies for Malignant Ascites. The companies which have their Malignant Ascites drug candidates in the most advanced stage, i.e. phase I include, YZY Biopharma.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Malignant Ascites pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation

Inhalation/Intravenous/Oral

Intranasal

Intravenous

Intravenous/ Subcutaneous

NA

Oral

Oral/intranasal/subcutaneous

Parenteral

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Antibody

Antisense oligonucleotides

Immunotherapy

Monoclonal antibody

Peptides

Protein

Recombinant protein

Small molecule

Stem Cell

Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant Ascites: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant Ascites therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Ascites drugs.

Malignant Ascites Report Insights

Malignant Ascites Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Malignant Ascites Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Malignant Ascites drugs?

How many Malignant Ascites drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Ascites?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malignant Ascites therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Malignant Ascites and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Sichuan Clover Biopharmaceuticals, Inc.

Wuhan YZY Biopharma Co., Ltd.

PharmaCyte Biotech

Y-mAbs Therapeutics

Key Products

SCB-313

M701

Microencapsulated CYP 2B1-expressing cells + ifosfamide

Omburtamab